Survodutide

Survodutide is a peptide investigated for metabolic conditions through activity at both GLP-1 and glucagon receptors. Research interests include obesity, appetite control, and glucose homeostasis, although the supplied guide does not establish clinical benefit.

GLP-1 receptor signaling participates in appetite regulation, gastric motility, and glucose-dependent insulin secretion. Glucagon receptor signaling influences hepatic glucose production and energy metabolism, making the combined metabolic response more complex than either pathway alone.

Survodutide has been investigated for concurrent activation of GLP-1 and glucagon receptors to influence food intake and metabolic processes. The guide proposes effects on satiety, lipid utilization, and insulin-related regulation, but does not provide evidence establishing the contribution of each pathway. Its characterization of the combined actions as synergistic requires independent verification.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 03 · Early human research

Small or early-stage human studies exist, with limited certainty and reproducibility.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents survodutide as a metabolic research candidate with potential relevance to obesity and type 2 diabetes. It attributes possible changes in body weight, glucose regulation, and fuel utilization to its two receptor targets. The guide also portrays tolerability favorably while listing gastrointestinal symptoms, tiredness, and lightheadedness, without supporting citations in the supplied extract.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The supplied material does not establish the magnitude, durability, or clinical significance of the proposed effects. Claims concerning enhanced fat breakdown, metabolic flexibility, and synergistic receptor activity need verification against primary research.

Safety data are limited in the supplied material, which reports nausea, vomiting, abdominal bloating, diarrhea, fatigue, and dizziness without documenting their frequency or severity. Slower gastric emptying is also mentioned, but its implications for nutrient absorption are not established by these notes. This summary is not medical advice.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “Survodutide dual receptor agonist”
• “Survodutide weight loss and appetite control”
• “Survodutide clinical trials for obesity and”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN